Document Detail


Tofacitinib in active ulcerative colitis.
MedLine Citation:
PMID:  23150971     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
To the Editor: Sandborn et al. (Aug. 16 issue)(1) report that tofacitinib has efficacy in the treatment of ulcerative colitis. The authors note that Janus kinase (JAK) inhibitors JAK1 and JAK3 are surprisingly ineffective in the treatment of Crohn's disease.(2) In Crohn's disease, the major cytokines arise from the differentiation of two subtypes of CD4+ T cells - Th1 and Th17 - whereas in ulcerative colitis a Th2-like differentiation process seems to be involved. Several recent reports on different experimental models seem to indicate that JAK inhibitors such as tofacitinib suppress Th2 but potentiate Th1 and Th17 responses. For example, . . .
Authors:
Mario Cottone; Ambrogio Orlando; Claudio Papi
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  The New England journal of medicine     Volume:  367     ISSN:  1533-4406     ISO Abbreviation:  N. Engl. J. Med.     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-15     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0255562     Medline TA:  N Engl J Med     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1959-61     Citation Subset:  AIM; IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Tofacitinib in active ulcerative colitis.
Next Document:  Effect of HIV-2 Infection on HIV-1 Disease Progression.